STTK insider transaction filings
Shattuck Labs, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-07. Screen STTK transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-07 | 4 | Shukla Abhinav A. — Chief Technical Officer | Option exercise (M): 410 @ $3.57 · Sale (S): 410 @ $7.01 · Option exercise (M): 12,153 @ $3.57 · Option exercise (M): 410 (derivative) @ $0 · Option exercise (M): 12,153 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Shukla Abhinav A. — Chief Technical Officer | Option exercise (M): 23,365 @ $3.57 · Sale (S): 23,365 @ $7.08 · Option exercise (M): 100 @ $3.57 · Sale (S): 100 @ $7.07 · Option exercise (M): 23,365 (derivative) @ $0 · Option exercise (M): 100 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Pandite Arundathy N. — Chief Medical Officer | Sale (S): 30,000 @ $7.01 | EDGAR |
| 2026-06-15 | 4 | Ashiya Mona — Director | Purchase (P): 1,041,667 (derivative) · Purchase (P): 208,333 (derivative) | EDGAR |
| 2026-06-15 | 4 | ORBIMED ADVISORS LLC — Director OrbiMed Capital GP IX LLC — Director OrbiMed Genesis GP LLC — Director | Purchase (P): 1,041,667 (derivative) · Purchase (P): 208,333 (derivative) | EDGAR |
| 2026-06-11 | 4 | SIEGALL CLAY B — Director | Purchase (P): 62,500 @ $4 | EDGAR |
| 2026-06-09 | 4 | Ashiya Mona — Director | Conversion (C): 15,366,490 (derivative) · Conversion (C): 3,073,298 (derivative) · Conversion (C): 15,366,490 (derivative) · Conversion (C): 3,073,298 (derivative) | EDGAR |
| 2026-06-09 | 4 | ORBIMED ADVISORS LLC — Director OrbiMed Capital GP IX LLC — Director OrbiMed Genesis GP LLC — Director | Conversion (C): 15,366,490 (derivative) · Conversion (C): 3,073,298 (derivative) · Conversion (C): 15,366,490 (derivative) · Conversion (C): 3,073,298 (derivative) | EDGAR |
| 2026-06-02 | 4 | Baker Daniel G. — Director | Grant/award (A): 81,000 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Ashiya Mona — Director | Grant/award (A): 81,000 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Boudreau Helen M — Director | Grant/award (A): 81,000 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Golumbeski George — Director | Grant/award (A): 81,000 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Gibson Neil W — Director | Grant/award (A): 81,000 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | SIEGALL CLAY B — Director | Grant/award (A): 81,000 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | SIEGALL CLAY B — Director | Grant/award (A): 128,054 @ $1.08 · Option exercise (M): 128,054 (derivative) | EDGAR |
| 2026-05-21 | 4 | Shukla Abhinav A. — Chief Technical Officer | Grant/award (A): 5,122 @ $1.08 · Option exercise (M): 5,122 (derivative) | EDGAR |
| 2026-05-18 | 4 | Stout Stephen — See Remarks | Grant/award (A): 12,805 @ $1.08 · Option exercise (M): 12,805 (derivative) | EDGAR |
| 2026-05-14 | 4 | Neill Andrew R — Chief Financial Officer | Grant/award (A): 64,027 @ $1.08 · Option exercise (M): 64,027 (derivative) | EDGAR |
| 2026-05-14 | 4 | Shukla Abhinav A. — Chief Technical Officer | Option exercise (M): 2,032 @ $3.57 · Sale (S): 2,032 @ $7.01 · Option exercise (M): 2,032 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | Pandite Arundathy N. — Chief Medical Officer | Sale (S): 30,000 @ $6.61 | EDGAR |
| 2026-05-13 | 4 | Schreiber Taylor — Chief Executive Officer, Director | Grant/award (A): 25,610 @ $1.08 · Option exercise (M): 25,610 (derivative) | EDGAR |
| 2026-05-12 | 4 | Stout Stephen — See Remarks | Tax withholding (F): 968 @ $6.85 | EDGAR |
| 2026-01-27 | 4 | Pandite Arundathy N. — Chief Medical Officer | Tax withholding (F): 3,195 @ $4.15 | EDGAR |
| 2026-01-27 | 4 | Stout Stephen — See Remarks | Tax withholding (F): 593 @ $4.15 | EDGAR |
| 2026-01-27 | 4 | Neill Andrew R — Chief Financial Officer | Tax withholding (F): 2,589 @ $4.15 | EDGAR |
| 2026-01-27 | 4 | DeYoung Casi — Chief Business Officer | Tax withholding (F): 2,286 @ $4.15 | EDGAR |
| 2026-01-13 | 4 | Stout Stephen — See Remarks | Tax withholding (F): 4,153 @ $4.75 · Grant/award (A): 351,400 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Shukla Abhinav A. — Chief Technical Officer | Grant/award (A): 315,500 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Pandite Arundathy N. — Chief Medical Officer | Tax withholding (F): 6,851 @ $4.75 · Grant/award (A): 487,800 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Neill Andrew R — Chief Financial Officer | Tax withholding (F): 6,660 @ $4.75 · Grant/award (A): 549,800 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | DeYoung Casi — Chief Business Officer | Tax withholding (F): 5,699 @ $4.75 · Grant/award (A): 381,600 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Schreiber Taylor — Chief Executive Officer, Director | Grant/award (A): 1,548,300 (derivative) @ $0 | EDGAR |
| 2025-09-02 | 4 | Ashiya Mona — Director | Grant/award (A): 66,300 (derivative) @ $0 | EDGAR |
| 2025-09-02 | 4 | Baker Daniel G. — Director | Grant/award (A): 66,300 (derivative) @ $0 | EDGAR |
| 2025-09-02 | 4 | Ashiya Mona — Director | Purchase (P): 5,255,106 @ $0.87 · Purchase (P): 1,051,021 @ $0.87 · Purchase (P): 10,111,384 (derivative) · Purchase (P): 2,022,277 (derivative) · Purchase (P): 15,366,490 (derivative) · Purchase (P): 3,073,298 (derivative) | EDGAR |
| 2025-09-02 | 4 | ORBIMED ADVISORS LLC — Director OrbiMed Capital GP IX LLC — Director OrbiMed Genesis GP LLC — Director | Purchase (P): 5,255,106 @ $0.87 · Purchase (P): 1,051,021 @ $0.87 · Purchase (P): 10,111,384 (derivative) · Purchase (P): 2,022,277 (derivative) · Purchase (P): 15,366,490 (derivative) · Purchase (P): 3,073,298 (derivative) | EDGAR |
| 2025-08-27 | 4 | Neill Andrew R — Chief Financial Officer | Grant/award (A): 64,027 @ $0.87 · Grant/award (A): 64,027 (derivative) | EDGAR |
| 2025-08-27 | 4 | Stout Stephen — See Remarks | Grant/award (A): 12,805 @ $0.87 · Grant/award (A): 12,805 (derivative) | EDGAR |
| 2025-08-27 | 4 | Shukla Abhinav A. — Chief Technical Officer | Grant/award (A): 5,122 @ $0.87 · Grant/award (A): 5,122 (derivative) | EDGAR |
| 2025-08-27 | 4 | Schreiber Taylor — Chief Executive Officer, Director | Grant/award (A): 25,610 @ $0.87 · Grant/award (A): 25,610 (derivative) | EDGAR |
| 2025-08-27 | 4 | SIEGALL CLAY B — Director | Grant/award (A): 128,054 @ $0.87 · Grant/award (A): 128,054 (derivative) | EDGAR |
| 2025-08-26 | 4 | Redmile Group, LLC — Director, 10% owner Green Jeremy — Director, 10% owner | Grant/award (A): 4,097,730 (derivative) · Grant/award (A): 4,097,730 (derivative) | EDGAR |
| 2025-07-16 | 4 | Lee Michael Stewart — Director | Grant/award (A): 33,150 (derivative) @ $0 | EDGAR |
| 2025-07-16 | 4 | Sasser Amy Kate — Director | Grant/award (A): 33,150 (derivative) @ $0 | EDGAR |
| 2025-07-16 | 4 | Brownstein Carrie — Director | Grant/award (A): 33,150 (derivative) @ $0 | EDGAR |
| 2025-07-16 | 4 | Brous Tyler — Director | Grant/award (A): 33,150 (derivative) @ $0 | EDGAR |
| 2025-07-16 | 4 | Boudreau Helen M — Director | Grant/award (A): 33,150 (derivative) @ $0 | EDGAR |
| 2025-07-16 | 4 | Golumbeski George — Director | Grant/award (A): 33,150 (derivative) @ $0 | EDGAR |
| 2025-07-16 | 4 | Gibson Neil W — Director | Grant/award (A): 33,150 (derivative) @ $0 | EDGAR |
| 2025-07-16 | 4 | Redmile Group, LLC — Director, 10% owner Green Jeremy — Director, 10% owner | Grant/award (A): 33,150 (derivative) @ $0 | EDGAR |
Recent 8-K events — Shattuck Labs, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2026-06-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-09 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-05 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-01-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2025-11-06 | 8-K/A | 2.02 — Results of Operations and Financial Condition | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=STTK returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →